clinical trial · NCT06860243
A Study to Evaluate Opevesostat (MK-5684) in Male Participants With Moderate Hepatic Impairment (MK-5684-009)
Merck Sharp & Dohme LLC·phase1·completed·n = 16
Hepatic ImpairmentHealthy ParticipantsOpevesostatPrednisoneFludrocortisone acetate
brief summary
Researchers have designed a study medicine called opevesostat as a new way to treat prostate cancer. The purpose of this study is to learn what happens to opevesostat in a person's body over time (a pharmacokinetic \[PK\] study). Researchers will compare what happens to opevesostat in the body when it is given to healthy participants and participants with moderate hepatic (liver) impairment.
started
May 13, 2025
primary completion
Feb 9, 2026
completion
Feb 19, 2026
last updated
Feb 24, 2026
official title
An Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of MK-5684 in Male Participants With Moderate Hepatic Impairment
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol